Catholic University of Daegu

About: Catholic University of Daegu is a education organization based out in Gyeongsan-si, South Korea. It is known for research contribution in the topics: Population & Apoptosis. The organization has 2745 authors who have published 5670 publications receiving 80311 citations.

Fabrication of Porous PZT–PZN Piezoelectric Ceramics With High Hydrostatic Figure of Merits Using Camphene‐Based Freeze Casting

Abstract: Porous lead zirconate titanate–lead zinc niobate (PZT–PZN) piezoelectric ceramics with interconnected pore channels were fabricated using the camphene-based freeze-casting method In this method, warm PZT–PZN/camphene slurries with various solid loadings (10, 15, 20, and 25 vol%) were prepared by ball milling at 60°C and then cast into molds at 20°C, resulting in the formation of solidified green bodies comprised of three-dimensionally interconnected camphene dendrite networks and concentrated ceramic particle walls After the removal of the frozen camphene via sublimation, the samples were sintered at 1200°C for 2 h All of the fabricated samples showed highly porous structures, consisting of fully dense PZT–PZN walls without defects, such as cracks or pores As the initial solid loading was decreased from 25 to 10 vol%, the porosity was linearly increased from 50% to 82% This increase in the porosity led to a reduction in the permittivity, a moderate decline in the d33 value, and a rapid decline in the d31 value, which endowed the porous samples with a high hydrostatic figure of merit (HFOM) The highest HFOM value of 35650 × 10−15 Pa−1 was achieved for the sample with a porosity of 82%, as well as ɛ33=284, dh=298 pC/N, and gh=118 × 10−3 V·(m·Pa)−1

Arthroscopic management of septic arthritis of the shoulder joint.

Abstract: Background: Nineteen patients with septic arthritis of the glenohumeral joint were treated with a combination of arthroscopic irrigation and debridement and systemic antibiotics according to bacterial sensitivity We retrospectively reviewed the series to determine the efficacy and safety of this treatment Methods: There were seventeen men and two women, with a mean age of fifty-nine years Underlying medical disease was present in thirteen patients, with six of them having diabetes The average duration of symptoms prior to the arthroscopic lavage was three weeks Fifteen patients had had local injections into the shoulder joint The arthroscopic staging of the infection was based on the modified criteria of Gachter The functional outcome was evaluated with use of the UCLA scoring system Results: As determined at arthroscopy, one infection was classified as stage I; seven, as stage II; nine, as stage III; and two, as stage IV Staphylococcus was the most common organism identified The infection was eradicated completely with a single arthroscopic procedure in fourteen patients The mean UCLA score at the time of the last follow-up was 26 points, with a mean score of 237 points for the eleven patients with a rotator cuff tear and 29 points for the eight with an intact rotator cuff Patients who had had symptoms for no more than two weeks prior to the arthroscopic lavage had better results than those who had had symptoms for longer than two weeks Conclusions: Arthroscopic debridement for the treatment of septic arthritis of the shoulder is safe and efficient, particularly in the early stages of the disease Underlying medical diseases such as diabetes, prior injections, or a preexisting rotator cuff tear were seen in a high proportion of these patients Level of Evidence: Therapeutic Level IV See Instructions to Authors for a complete description of levels of evidence

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

Abstract: Objectives Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those in patients who maintained treatment with INF or SB2. Methods Patients with moderate to severe RA despite methotrexate treatment were randomised (1:1) to receive SB2 or INF at weeks 0, 2 and 6 and every 8 weeks thereafter until week 46. At week 54, patients previously receiving INF were rerandomised (1:1) to switch to SB2 (INF/SB2 (n=94)) or to continue on INF (INF/INF (n=101)) up to week 70. Patients previously receiving SB2 continued on SB2 (SB2/SB2 (n=201)) up to week 70. Efficacy, safety and immunogenicity were assessed up to week 78. Results Efficacy was sustained and comparable across treatment groups. American College of Rheumatology (ACR) 20 responses between weeks 54 and 78 ranged from 63.5% to 72.3% with INF/SB2, 66.3%%–69.4% with INF/INF and 65.6%–68.3% with SB2/SB2. Treatment-emergent adverse events during this time occurred in 36.2%, 35.6% and 40.3%, respectively, and infusion-related reactions in 3.2%, 2.0% and 3.5%. Among patients who were negative for antidrug antibodies (ADA) up to week 54, newly developed ADAs were reported in 14.6%, 14.9% and 14.1% of the INF/SB2, INF/INF and SB2/SB2 groups, respectively. Conclusions The efficacy, safety and immunogenicity profiles remained comparable among the INF/SB2, INF/INF and SB2/SB2 groups up to week 78, with no treatment-emergent issues or clinically relevant immunogenicity after switching from INF to SB2. Trial registration number NCT01936181; EudraCT number: 2012-005733-37.